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Abstract Overexpression of the major vault protein (MVP) has
been linked to a multidrug resistance (MDR) phenotype. We
describe a ubiquitously expressed MVP mRNA splice variant
(long (L)-MVP) differing from the regular isoform (short (S)-
MVP) within the 5P-leader. Only L-MVP mRNA contains a
small upstream open reading frame which was proven to inhibit in
vitro and in vivo MVP expression in cis. L-MVP represented an
almost constant portion of total MVP mRNA in diverse normal
tissues, but was more variable in malignant cell types. MDR
sublines with altered MVP expression displayed changed S-
MVP/L-MVP ratios as compared to their drug-sensitive
counterparts. Our results suggest alternative splicing as one
mechanism for regulation of MVP expression. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
Key words: Major vault protein; Lung resistance protein;
Alternative splicing; 5P-Untranslated region; Upstream open
reading frame; Translational repression
1. Introduction
Vaults are ubiquitously expressed ribonucleoprotein par-
ticles containing multiple copies of three di¡erent proteins
as well as an untranslated RNA [1]. The evolutionary conser-
vation and widespread expression of vaults suggest a basic,
yet unknown, cellular function. The three-dimensional hollow
structure points to a role in transport processes [2] and indeed
vaults were suggested to regulate nucleo-cytoplasmic transport
[3]. The major vault protein (MVP) is identical to the lung
resistance-related protein (LRP) [4]. Vaults are overexpressed
in a variety of multidrug-resistant (MDR) cell lines [5] and
MVP expression predicts chemotherapy failure in several ma-
lignancies [6]. Little is known about factors involved in the
regulation of MVP expression. In normal tissues, high
amounts are present in potentially drug-exposed epithelia
and macrophages [7]. MVP expression can be up-regulated
by a short-term exposure to chemotherapeutic or di¡erentia-
tion-inducing agents [8,9]. Discordance between MVP mRNA
and protein expression in several cell types points to a sub-
stantial in£uence of posttranscriptional regulatory mechanism
[8^10].
Here we describe and characterise a ubiquitously expressed
but translationally repressed MVP mRNA splice variant
which has very recently also been identi¢ed in an MVP-pro-
moter study [11]. The expression pattern in normal and tu-
mour tissues as well as MDR cell models suggested that alter-
native splicing might be involved in posttranscriptional
regulation of MVP expression.
2. Materials and methods
2.1. Cell lines
The brain tumour cell line KM-YH was established from patient
material; MR-1 glioblastoma cells were a gift of Dr. T. Kurata, To-
kyo, Japan. Data on 16 NSCLC cell lines, BEAS-2B and F2000 have
been described elsewhere [12]. Generous donors and characterisation
of MDR cell models have been described [13]: GLC4 and GLC4/
ADR [14]; SW1573, SW1573/2R120 and SW1573/2R160 [15]; 8226/
S, 8226/DOX6 and 8226/DOX40 [16].
2.2. cDNA, monoclonal antibodies (mAbs) and chemicals
Multiple tissue cDNA panels (MTC Panels I and II, Human Tumor
MTC Panel) were obtained from Clontech (Palo Alto, CA, USA).
Two MVP mAbs LRP56 (IgG2b, Sanbio, Uden, The Netherlands)
and LRP (IgG1, Pharmingen/Transduction Laboratories, San Diego,
CA, USA) were used for immuno£uorescence staining and Western
blot analysis, respectively. The isotype control antibody and all other
chemicals used were obtained from Sigma (St. Louis, MO, USA).
2.3. EST clones, sequence analysis
EST cDNA clones IMAGE:2222005, 363900, 2276385 and
DKFZp434L1720 were obtained from the German Human Genome
Project Resource Center (RZBD, Berlin, Germany) and the UK
HGMP Resource Centre (Cambridge, UK). For clones IM-
AGE:2222005 and 2276385 cDNA 5P-sequences were determined by
automated sequencing (VBC Genomics, Vienna, Austria) and depos-
ited in GenBank/EMBL/DDBJ (accession numbers AJ291369,
AJ291368). For ampli¢cation of the intron sequence the Expand
Long Template PCR System (Roche Molecular Biochemicals, Mann-
heim, Germany) was used, and for primer-mediated mutagenesis re-
combinant pfu DNA polymerase (Stratagene, La Jolla, CA, USA)
was used. Polymerase chain reaction (PCR) products have been in-
troduced for sequencing into pCR2.1-TOPO vector (Invitrogen, Gro-
ningen, The Netherlands).
2.4. MVP plasmid construction
The expression vector constructs S-MVP-1 and S-MVP-2 were ob-
tained using the EST clones IMAGE:2276385 and 2222005, respec-
tively. cDNA inserts were cloned between the SalI and NotI sites of
pCMV-SPORT6. For construction of long (L)-MVP an EcoRI and
NotI cDNA fragment from DKFZp434L1720 was introduced into
pCMV-SPORT6. To generate the S-MVP-3 construct a XbaI frag-
ment from L-MVP was replaced by the corresponding fragment
from S-MVP-2. To introduce mutations into the upstream open read-
ing frame (uORF) a primer-mediated mutation procedure was chosen.
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First, using the primers M13-reverse 5P-GGAAACAGCTATGAC-
CATG-3P and MVP-10-as 5P-CTAGAAGTGCAGGTAGCTG-3P a
150 bp upstream fragment was ampli¢ed. Then either a primer con-
taining a point mutation in the uORF start codon (MVP-M1-s 5P-
CCTGCACTTCTAGTTGCCTCCCCAGG-3P) or a frameshift (31)
following the start codon (MVP-M2-s 5P-CCTGCACTTCTA-
GATGTCCCCAGGTT-3P) were combined with MVP-22-as: 5P-CA-
CAGGGTTGGCCACTGTGCA-3P to amplify mutated 280 bp down-
stream fragments. Fragments were fused together (overlapping regions
are underlined) by ampli¢cation with primers M13-reverse and MVP-
22-as. The EcoRI and BstXI fragments were exchanged with the re-
spective fragment in L-MVP resulting in L-MVP-mut1 and L-MVP-
mut2 constructs. The sequences of all constructs were proven by au-
tomated sequencing.
2.5. In vitro transcription/translation
In vitro transcription/translation experiments with the respective
MVP constructs were performed using the TNT coupled reticulocyte
lysate system (Promega, Madison, WI, USA) according to the man-
ufacturer’s protocol. Incorporated radioactivity was quanti¢ed using
the Molecular Dynamics phosphoimager system (Sunnyvale, CA,
USA). Results are given as means of at least three independent experi-
ments.
2.6. Transfection experiments, Western blotting and
immuno£uorescence staining
Cells were transfected with MVP constructs by electroporation us-
ing standard protocols. For transient experiments, cells were har-
vested after a 48 h incubation and total cell extracts prepared as
described [12]. For stable transfection, MVP constructs were co-trans-
fected with a puromycin resistance construct in a ratio 10:1. Resistant
clones were isolated, propagated and total cell extracts prepared.
SDS^PAGE and Western blot analysis were performed as described
[12]. MVP expression in NSCLC cells was quanti¢ed relatively (arbi-
trary units) to extracts of strongly MVP-expressing embryonic ¢bro-
blasts F2000 [9]. All results are means of at least three experiments.
2.7. Reverse transcription (RT)-PCR
MVP mRNA isoform expression in tissues and cell lines was deter-
mined by RT-PCR analysis. Either total cellular RNA was reverse
transcribed [12] or cDNA panels (Clontech) were used. PCR was
performed [12] using several oligonucleotide primers: MVP-3-s 5P-
TTCTGGATTTGGTGGACG-3P and MVP-3-as 5P-ACTTCTCT-
CCCTTGACCA-3P ampli¢ed a 284 bp fragment within the MVP
ORF; MVP-49-s 5P-GTTCCCCATCTGAGGCGT-3P and MVP-50-
as 5P-CTGCCGGATGTAGGTCTT-3P ampli¢ed a 235 bp fragment
of L-MVP and a 193 bp fragment of S-MVP; MVP-44-s 5P-
GGTTCATCCTGTGTCGTCTC-3P corresponds to a sequence within
the uORF and ampli¢ed, in combination with MVP-50-as, a 181 bp
product speci¢c for L-MVP. PCR ampli¢cation was performed in the
exponential proportion of the reaction. Quanti¢cation of MVP iso-
forms was done at 25^30 cycles, depending on the MVP mRNA ex-
pression level. Results given are the means of three independent ex-
periments. Standard deviations were below 13%.
3. Results
3.1. 5P-Region of the MVP gene
Using the published human MVP cDNA sequence
(X79882) [4] several homologous clones were identi¢ed in an
EST database di¡ering within the 5P-untranslated region
(UTR) of the MVP gene. Two of four EST sequences con-
tained an additional 41 bp stretch located 35 bp upstream of
the initiation start codon. Consequently, we ampli¢ed the cor-
responding region from cDNA and genomic DNA derived
from A549 cells. RT-PCR resulted in the ampli¢cation of
two DNA fragments di¡ering by 41 bp in length. Ampli¢ca-
tion from genomic DNA led to one 10 kb fragment. The
respective PCR products were cloned and sequenced (acces-
sion numbers AJ291366, AJ291367, AJ291364, AJ291365).
Fig. 1 summarises the situation at the 5P-region of the MVP
Fig. 1. 5P-Region of the MVP gene: genomic sequence, mRNA iso-
forms and expression constructs. A: Genomic sequence; SD and
two di¡erent SA sites are indicated by the respective consensus se-
quences (SDcon and SAcon, respectively). Bold face depicts exons.
The additional 41 bp in L-MVP are shown in lowercase letters. The
translation of the uORF and nine N-terminal residues of the MVP
ORF are given. Start codons are underlined. Usage of the down-
stream SA site does not lead to an ATG start codon and conse-
quently a uORF as in case of the upstream SA site. B: Generation
of S-MVP and L-MVP by alternative splicing (broken lines). The
isoforms di¡er with respect to the additional 41 bp in L-MVP
mRNA (thin line). Hatched box and the open box depict the MVP
ORF and the uORF, thick and thin lines, exons and introns, respec-
tively. C: MVP constructs: promoters for in vitro (PSP6) and in
vivo (PCMV) transcription are indicated. The S-MVP constructs 1, 2
and 3 vary only in the length of their 5P-UTR upstream of the al-
ternative splice site.
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gene on the genomic and transcript level. Consensus splice
donor (SD) and splice acceptor (SA) sequences (Fig. 1A) sug-
gested the presence of a 10 kb intron located in the 5P-UTR of
the MVP gene which was proven by the sequence of the short-
er cDNA fragment. The longer cDNA fragment contained an
additional 41 bp stretch derived from the 3P-end of the intron
sequence. This situation together with the presence of second
consensus SA sequence (Fig. 1A) indicated that the two
mRNA isoforms originate from alternative splicing (Fig.
1B). The L-MVP mRNA contained an initiation start codon
located in the 5P-UTR thus opening a uORF encoding 18
amino acids, whereas the short one (S-MVP mRNA) lacked
any upstream initiation start codons (Fig. 1A,B).
To analyse the in£uence of the 5P-leader sequence on MVP
expression, constructs that di¡er in their 5P-UTR (Fig. 1C)
have been created. To determine an in£uence of the far-end
5P-sequence on MVP expression, which varies between
X79882 and EST sequences, three di¡erent constructs for S-
MVP slightly di¡ering in the length of the 5P-UTR were used
(S-MVP-1 to -3). The MVP expression constructs S-MVP-3
and L-MVP di¡er only with respect to the 41 bp stretch
caused by alternative splicing. To test the in£uence of
the uORF, either the initiation start codon was mutated
(L-MVP-mut1) or a 1 bp deletion was introduced (L-MVP-
mut2).
3.2. Expression of MVP from mRNA isoforms
Fig. 2 summarises the expression of MVP from the inves-
tigated MVP constructs (Fig. 1C) in an in vitro transcription/
translation system (Fig. 2A) and when transfected into MVP-
negative KM-YH cells in either a transient (Fig. 2B) or a
stable (Fig. 2C) setting. In both the in vitro and in vivo assays
the three S-MVP constructs (S-MVP-1 to -3) led to a compa-
rable synthesis of a 110 kDa protein which represented MVP
as proven by immunoblot detection (Fig. 2A,B). When using
the L-MVP construct in vitro only around 20% of MVP as
compared to the S-MVP constructs was expressed (Fig. 2A).
A point mutation within the uORF start codon (L-MVP-
mut1) completely abolished suppression of MVP expression.
Also a changed nature of the uORF (L-MVP-mut2) signi¢-
cantly up-regulated MVP expression, however, only to around
40% as compared to S-MVP constructs. In a transient setting
Fig. 2. (continued).
Fig. 2. MVP expression from MVP constructs. A: In vitro MVP ex-
pression from the indicated constructs. B: Transient expression of
MVP in KM-YH cells from the indicated constructs. MVP mRNA
isoform (upper panel) and MVP expression (lower panel) were ana-
lysed by RT-PCR and Western blot, respectively. For RT-PCR
(upper panel) the following primers were used: MVP-49-s, MVP-50-
as, lane 1; MVP-3-s, MVP-3-as, lane 2; GAPDH primers, lane 3.
Representative results for S-MVP-3 and L-MVP are shown. In case
of Western blot analysis (lower panel), bars represent optical density
(OD) values from scanned autoradiograms (means, S.D. of three in-
dependent experiments). One representative experiment is shown as
inset. In A and B values for S-MVP-3 were arbitrarily set as 100%.
C: MVP expressions in stable transfected KM-YH cell clones (vec-
tors as indicated) were analysed by immuno£uorescence (upper pan-
el) and Western blot (lower panel). MR-1 glioblastoma cells served
as MVP positive control.
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in vivo (Fig. 2B, lower panel), MVP expression from the
L-MVP construct was completely suppressed and comparable
to the vector control. Both L-MVP-mut1 and L-MVP-mut2
partially (60^80% of S-MVP) released suppression of MVP
expression. The lack of MVP expression from L-MVP did
not rest on a markedly altered stability of L-MVP mRNA
as demonstrated by RT-PCR (Fig. 1B, upper panel). In the
case of stable transfection, the use of S-MVP but not L-MVP
constructs led to MVP-expressing subclones, as could be dem-
onstrated by immunoblot and immuno£uorescence analysis
(Fig. 2C). Transient transfection experiments using the
NSCLC cell line VL-4 led to comparable results with regard
to MVP (not shown).
3.3. Expression of the two MVP mRNA isoforms in benign and
malignant tissues and cells
mRNA preparations from several normal and malignant
tissues and cell lines were investigated by an RT-PCR setting
allowing the simultaneous detection of L-MVP and S-MVP
isoforms (Fig. 3A). In each RNA pool analysed, both MVP
mRNA isoforms were detectable; however, S-MVP was al-
ways the dominant isoform. Fig. 3B summarises the ratio
between the two MVP mRNA isoforms in a panel of normal
tissues, demonstrating that the suppressed L-MVP isoform
represents almost constantly about 35^45% of total MVP
mRNA. Only the brain cDNA contained merely 28% L-
MVP mRNA. In malignant tissues the MVP mRNA isoform
ratio was more variable as compared to normal tissues (Fig.
3C,D). When analysing a panel of NSCLC cell lines (N = 16)
L-MVP/S-MVP ratios between 0.27 and 1 were detected (Fig.
3D). When the NSCLC cell lines were grouped regarding their
isoform ratio 6 and s 0.5, the low isoform ratio indicated a
high MVP expression (30.5 þ 27.6; N = 6) as compared to the
high ratio (7.4 þ 8.7; N = 10) (P6 0.05, unpaired t-test), inde-
pendent of the general MVP mRNA expression level (not
shown).
3.4. Expression of the two MVP mRNA isoforms in
MDR cell models
Three MDR cell models containing drug-sensitive parental
cell lines and drug-selected sublines were investigated (Fig. 4).
In the case of the GLC4 cells a concordant increase of both
MVP mRNA isoforms was detectable in the markedly MVP-
overexpressing subline GLC4/ADR, resulting in a moderate
increased isoform ratio. In contrast, in the SW1548 cell model
the MVP-overexpressing subline 2R120 displayed a signi¢-
Fig. 3. Expression of MVP mRNA isoforms in normal and malignant cells. A: Simultaneous detection of L-MVP and S-MVP by PCR. Indi-
cated proportions of S-MVP and L-MVP constructs (given as ratio L-MVP/S-MVP) were mixed and PCR performed with the oligonucleotide
primers MVP-49-s and MVP-50-as (upper panel). Oligonucleotide primers MVP-3-s and MVP-3-as ampli¢ed a fragment of the MVP coding re-
gion (lower panel). B^D: Expression of MVP mRNA isoforms in (B) normal tissues, (C) malignant cell lines of mixed histology (GI-101, breast
carcinoma; LX-1, GI-117, lung carcinoma; GI-103, pancreatic adenocarcinoma; PC3, prostatic adenocarcinoma; GI-102, ovarian carcinoma;
CX-1, GI-112, colon adenocarcinoma) and (D) a panel of 16 NSCLC cell lines, BEAS-2B and F2000 cells was analysed by RT-PCR. Represen-
tative experiments are shown as insets. In D the ¢rst lane for each cell line in the inset shows ampli¢cation products obtained with an upstream
primer hybridising in the 41 bp sequence unique to the L-MVP mRNA (MVP-44-s).
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cantly reduced isoform ratio as compared to the (low MVP-
expressing) parental line. The highly P-glycoprotein-overex-
pressing, but almost MVP-negative, subline 2R160 was char-
acterised by a slightly enhanced L-MVP ratio as compared to
the parental cell line. The multiple myeloma cell line 8226/S
and its P-glycoprotein-overexpressing sublines DOX6 and
DOX40 all expressed comparable high MVP levels. The
MVP mRNA isoform ratio of these cell lines was almost
constant.
4. Discussion
In eukaryotic cells, translational control in several gene
types is mediated via cis-acting elements in the 5P- or
3P-UTR of the mRNA. The presence of upstream AUGs
and associated uORFs, although generally rare in mRNAs
(around 5^10% of the human genes), is a common occurrence
in proto-oncogenes, growth factor and growth factor receptor
genes as well as other genes involved in cell growth and di¡er-
entiation [17,18], including for example mdm-2 [19], bcl-2 [20]
and TIMP [21]. Repression of translation of the downstream
ORF by one up to several uORFs, is a key regulator in tissue-
speci¢c gene regulation and developmental control [22]. With
regard to MVP, the identi¢cation of a uORF in a ubiqui-
tously expressed mRNA isoform might point to an important
cellular function of MVP, respectively vaults, as has also been
suggested due to the high evolutionary conservation and the
widespread expression [4,7].
Several mechanisms have been shown to cause the trans-
lational repression of the downstream ORF by a uORF:
(1) Ribosomes scan along the 5P-UTR, presumably translate
the uORF and are unable to reinitiate at the downstream
ORF, as demonstrated for example in case of Her-2/neu
[23]. (2) The encoded peptide of the uORF might be trans-
lated and inhibits sequence-dependent and in cis-downstream
translation, probably by stalling the translation machinery, as
shown, for example, in the s-adenosylmethionine decarboxyl-
ase mRNA [24]. (3) Presence of the uORF, its translation or,
more likely, translation termination [25] might destabilise the
mRNA molecule and enhance its decay rate.
Expression of MVP from L-MVP was intensely repressed in
vivo, reaching almost 100% in KM-YH cells. As a general rule
single uORFs only weakly (10^40%) inhibit translation. Our
results are even more surprising insofar as the uORF in
L-MVP has no optimal context for initiation of translation
[17]. This suggests a combination of several mechanisms caus-
ing the very potent translational suppression in case of
L-MVP. A point mutation within the start codon of the
uORF as well as insertion of a frameshift within the uORF
derepressed translation at almost comparable levels pointing
to a predominant sequence-speci¢c activity of the uORF. It
has, however, to be taken into account that the altered uORF
in construct L-MVP-mut2 is terminated by a di¡erent stop
codon, thus shortening the spacer between uORF and ORF
and perhaps thereby in£uencing translational repression [26].
Additionally, the release of suppression with both mutated
constructs in vivo was not complete (60^80%), suggesting
that the translation suppression might not entirely rest on
the uORF. For example the presence of secondary structures
with a stronger free energy in L-MVP might hamper ribosome
scanning [17]. Taken together, several mechanisms are sug-
gested to contribute to the surprisingly high repression of
the MVP expression from L-MVP mRNA in vivo. The nature
and importance of these mechanisms have to be dissected by
further investigations. Results from the in vitro assay di¡ered
from the in vivo analysis. The suppression of MVP expression
from L-MVP was less pronounced as compared to the in vivo
experiments. A point mutation within the start codon of the
uORF completely released suppression of MVP expression in
vitro. In contrast, insertion of a frameshift within the uORF
only weakly up-regulated MVP expression. Thus, the results
of the reticulocyte lysate assay point to a loss of the sequence-
dependency during preparation of the extracts.
The physiological role of the ubiquitously expressed but
translationally suppressed MVP mRNA isoform is enigmatic,
in particular as the basic cellular function of MVP is still
unclear. In normal tissues, constantly about 30^45% of the
total MVP mRNA is present in the form of the repressed
L-MVP mRNA. Only the brain tended to contain relatively
lower amounts of L-MVP mRNA perhaps corresponding to a
general di¡erence of mRNA splicing in neuronal tissues [27].
The enhanced variability of MVP mRNA isoform expression
in malignant tissue corroborates data indicating a deregula-
tion of MVP expression during malignant transformation [28].
Regarding drug resistance, MDR sublines characterised by
MVP overexpression were demonstrated to di¡er from the
parental line with regard to the MVP mRNA isoform ratio
indicating that posttranscriptional events might play an essen-
tial role in the acquisition of an MDR phenotype.
Summing up, we demonstrate for the ¢rst time that alter-
native splicing might have an impact on the expression of the
MVP gene. Interestingly, the depicted splicing event does not
lead to an altered MVP ORF, but rather to an mRNA con-
trolled by a small uORF. Such a complex combination of
gene expression regulation by alternative splicing and a trans-
lational control via the 5P-leader is almost unique to MVP so
far. It suggests the necessity for a precise regulation of MVP
expression, as is known for proteins serving essential functions
in cell growth, di¡erentiation and tissue homeostasis [17].
Fig. 4. Expression of MVP mRNA isoforms and MVP in MDR cell
models. MVP mRNA isoforms as indicated (middle panel) and de-
rived isoform ratios (bars in lower panel) were determined as de-
scribed in Fig. 3 and compared to Western blot analysis (upper
panel).
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